L-Glutamine

Catalog No.S1749

For research use only.

L-Glutamine (Gln) is one of the 20 amino acids encoded by the standard genetic code and also a major respiratory fuel and substrate for nucleic acid synthesis in mammalian intestinal cells.

L-Glutamine Chemical Structure

CAS No. 56-85-9

Selleck's L-Glutamine has been cited by 2 Publications

Purity & Quality Control

Related Other Products

Biological Activity

Description L-Glutamine (Gln) is one of the 20 amino acids encoded by the standard genetic code and also a major respiratory fuel and substrate for nucleic acid synthesis in mammalian intestinal cells.
In vitro

L-Glutamine (0.2 and 2 mM) but not D-Gln inhibits the generation of L-Arg by both Arg-depleted and nondepleted endothelial cells. L-Glutamine also inhibits the conversion of L-[14C]Cit to L-[14C]Arg by Arg-depleted endothelial cells. L-Glutamine interferes with the conversion of L-Cit to L-Arg probably by acting on argininosuccinate synthetase rather than argininosuccinate lyase. L-Glutamine also inhibits the generation of L-Arg by the monocyte-macrophage cell line J774 but has no effect on the conversion of L-Cit to L-Arg by these cells. [1] L-Glutamine metabolism stimulates Na+-H+exchange of acid-loaded porcine enterocytes by a mechanism not requiring activation of PKC. [2] L-Glutamine (0.2 mM and 2 mM) but not D-glutamine (2 mM), L-glutamic acid (2 mM) or ammonium chloride (1 mM) also inhibits the generation of L-arginine in endothelial cells. [3] L-glutamine promotes chromatin condensation and formation of crescent-like structures in the nucleus of murine primary microglia as well as of the microglial cell-line BV-2. [4]

In vivo L-Glutamine at 0.5, 2 and 5 mM dose-dependently reduces H(2)O(2)- or LPS-induced cell death by 14%, 54% and 95%. L-Glutamine increases Glutamine concentrations in small-intestinal lumen and plasma, reduces intestinal expression of Toll-like receptor-4, active caspase-3 and NFkB, ameliorates intestinal injury, decreases rectal temperature, and enhanced growth performance in LPS-challenged piglets. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 146.14
Formula

C5H10N2O3

CAS No. 56-85-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C(CC(=O)N)C(C(=O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04785989 Recruiting Other: [U-13C]glucose|Other: [13C5]glutamine Chronic Lymphocytic Leukemia University of Wisconsin Madison June 13 2022 Early Phase 1
NCT04634539 Recruiting Drug: Gemcitabine|Drug: Nab-paclitaxel|Drug: L-glutamine Advanced Pancreatic Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Jun Gong MD|Emmaus Medical Inc.|Cedars-Sinai Medical Center May 13 2021 Phase 1
NCT04684381 Recruiting Drug: L-glutamine Sickle Cell Disease|Pharmacokinetics Emmaus Medical Inc. January 4 2021 Phase 4
NCT05106101 Active not recruiting Drug: L-glutamine Diverticulosis Colonic Emmaus Medical Inc. July 19 2019 Phase 1
NCT00922688 Unknown status Drug: Dipeptide Alanyl-Glutamine|Drug: Placebo Colon Carcinoma Medical Center Alkmaar December 2010 Not Applicable
NCT01179217 Completed Drug: L-glutamine|Drug: Placebo Sickle Cell Anemia|Sickle ß0-Thalassemia Emmaus Medical Inc. May 2010 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy L-Glutamine | L-Glutamine ic50 | L-Glutamine price | L-Glutamine cost | L-Glutamine solubility dmso | L-Glutamine purchase | L-Glutamine manufacturer | L-Glutamine research buy | L-Glutamine order | L-Glutamine mouse | L-Glutamine chemical structure | L-Glutamine mw | L-Glutamine molecular weight | L-Glutamine datasheet | L-Glutamine supplier | L-Glutamine in vitro | L-Glutamine cell line | L-Glutamine concentration | L-Glutamine nmr